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Symptom severity of bipolar disorder
during the menopausal transition
Wendy K. Marsh1*, Bernice Gershenson2 and Anthony J. Rothschild3
Abstract
Background: Little is known about the mood symptom experience of women with bipolar disorder during the
menopausal transition (MT). Yet times of rapid hormonal decline, such as the postpartum, are associated with
increased risk of severe mood episodes in bipolar disorder, and the MT is a time of increased risk for unipolar
depression in women with or without a history of depression.
Methods: Enrollment included 56 women 40–60 years old diagnosed in the bipolar spectrum who were
experiencing menopausal symptoms or were up to 5 years since their final menstrual period. Menopausal
stages included early menopause, late menopause, or early postmenopause based on standardized criteria.
Observational, prospective standardized mood symptom and reproductive hormone assessments were
completed periodically. Concurrent menopausal symptoms as well as history of mood exacerbation during
past reproductive events were assessed.
Results: Forty-four women were included in the main analysis. The average Montgomery-Asberg Depression
Rating Scale (MADRS) score was 4.43 points higher in the late transition/early postmenopausal stage women
(n = 29) compared to the early menopausal stage women (n = 15) (±SE 2.14; p = 0.039), corresponding to a
roughly 10 % higher score (range 0–40) in the late/post stage across all study visits. Results were similar for
the Young Mania Rating Scale (YMRS), where the average score was 2.54 points higher in the late/early
postmenopausal stage women compared to the early menopausal stage women (±SE 1.15; p = 0.027), also
roughly 10 % higher (range 0–26). Estradiol and follicle-stimulating hormone (FSH) absolute levels as well as
between-visit change in levels were not notably associated with YMRS or MADRS during study observation.
Total Greene Climacteric Symptom (menopausal symptom) score was significantly associated with MADRS but
not YMRS. History of mood exacerbation premenstrually and/or postpartum was not significantly associated
with YMRS or MADRS severity during the MT.
Conclusions: These results support the theory that times of increased reproductive hormonal changes, such
as the late MT and early postmenopause, here compared to early MT, are associated with greater mood symptom
severity in bipolar spectrum women. Nonetheless, absolute or change in FSH and estradiol levels were not significantly
associated with depression or mood elevation severity.
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Background
Due to the scarcity of studies, little is known about
the course of bipolar disorder through the perimeno-
pause, or menopausal transition (MT), and yet every
woman with bipolar disorder expects to or has experi-
enced menopause. Compelling evidence on the increased
risk of mood episodes in women with bipolar disorder
(BD) during other times of reproductive hormonal transi-
tion, like postpartum (Kendell et al. 1987; Sit et al. 2006),
indicates the importance of examining mood during the
menopausal transition. Given the substantial societal bur-
den of bipolar disorder (Kleine-Budde et al. 2013), detect-
ing times of risk is critical.
Psychological symptoms in women without a mood
disorder are frequent during the MT and most often
include irritability, tearfulness, anxiety, depression, emo-
tional lability, low energy and motivation, poor concen-
tration, and interrupted sleep (Avis et al. 1994). While
the role of reproductive hormones in the risk of mood
symptoms is unclear, psychological symptoms are postu-
lated to be linked to the fluctuation, not absolute levels,
of estradiol (Rubinow et al. 1998). These psychological
symptoms overlap with those of functionally impairing
mood disorders leading one to speculate that the peri-
menopause may contribute to depression or mood eleva-
tion in vulnerable women.
Unipolar depression risk in the MT has an expanding
literature reporting an increase of both major depression
and depressive symptoms during the perimenopause
(Maartens et al. 2002; Freeman et al. 2004a; Schmidt
et al. 2004; Bromberger 2006; Cohen et al. 2006; Steinberg
et al. 2008). Compared with premenopausal women,
women with a history of depression are nearly five times
more likely to have a diagnosis of major depression in the
menopausal transition, whereas women with no his-
tory of depression are two to four times more likely
to report depressed mood (Freeman 2010). Within
the Stages of Reproductive Aging Workshop + 10
(Harlow et al. 2012) defined reproductive stages, the
late perimenopause (interval of amenorrhea of 60 to
364 days) (Dennerstein et al. 1993; Schmidt et al.
2004; Freeman et al. 2006; Bromberger et al. 2007;
Woods et al. 2008; Freeman 2010; Bromberger et al. 2011)
and early postmenopause (amenorrhea 1–6 years)
(Dennerstein et al. 2004; Bromberger et al. 2007;
Bromberger et al. 2011) are times of heightened risk
of unipolar depression. Women reporting a history of
premenstrual or postpartum mood disturbance are at
greater risk of depression during the MT than those who
do not (Freeman et al. 2004b; Freeman 2010).
Less is known in bipolar disorder. Postmenopausal
women recalling the MT report severe mood distur-
bances or worsening depression during the transition
(Blehar et al. 1998; Freeman et al. 2002). Mood
elevation is reported less frequently than depression
in the MT (Blehar et al. 1998; Kennedy et al. 2005).
Our work reviewing longitudinal standardized clinical
assessments in menopausal age women with bipolar
disorder found a high degree of depression, 68 % over
a 17-month average duration, that was significantly
greater than what subjects reported experiencing during
their reproductive years (Marsh et al. 2008). Compared to
a concurrent pooled comparison group of like-aged men
and reproductive age women with bipolar disorder,
women of menopausal age with bipolar disorder had a sig-
nificantly greater proportion of clinic visits in the de-
pressed state and significantly lower proportion in the
euthymic state, with no difference in proportion of visit in
the elevated/mixed state (Marsh et al. 2009). When exam-
ining mood by menopausal stage in a large multisite data-
base of patients treated for bipolar disorder, the small
number of women transitioning from perimenopause to
postmenopause had significantly greater depression than
other female reproductive groups while overall euthymia
and mood elevation decreased with progressing female re-
productive stage (Marsh et al. 2012). Nonetheless, there is
a lack of prospective data on mood experience during this
critical time in bipolar disorder.
This study prospectively examines mood across the
MT stages and in association with reproductive hor-
mones in women with bipolar disorder. We hypothe-
sized that depression scores would be higher during the
late menopausal transition and at times of greater hor-
monal changes.
Methods
Study participants
Study enrollment occurred from January 2010 to July
2012, and subjects were recruited from the commu-
nity as well as from an academic psychiatry clinic.
Eligibility included (a) a diagnosis of bipolar disorder
(I, II, NOS) based on DSM IV criteria, (b) age 40–60
years with intact uterus and ovaries, (c) a menstrual
period within the last 5 years, if menstruating regu-
larly (every 21–35 days) subject must be experiencing
menopausal symptoms, and (d) having a current psy-
chiatric provider. Menopausal symptoms were defined
narrowly as vasomotor symptoms (hot flashes and
night sweats) so as not to overlap with mood symp-
toms (for example, sleep disturbance and irritability).
As study personnel did not assume care of subjects,
for subject safety, a psychiatric provider was required.
Women using vaginal hormone therapy (n = 1) or intra-
uterine device with hormonal progesterone (n = 1) were
accepted; those on oral contraceptives were not. Partici-
pants provided signed, written informed consent prior to
study entry.
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Procedures
This study conducted an observational longitudinal
evaluation of mood for 4 months during each of the
following menopausal stages: late reproductive, early
menopausal transition, late menopausal transition,
and early postmenopause (defined in the “Menopausal
status” section below) in women with bipolar dis-
order. The initial interview was scheduled in the
early follicular phase on days 2–6 of the menstrual
cycle (day 1 being the first day of menstruation) in
women who were menstruating more frequently than
every 60 days for standardized hormonal assessments.
Initial visit included a standardized interview with the
Affective Disorder Evaluation (ADE), a modified ver-
sion of the mood and psychosis modules from the Struc-
tured Clinical Interview for DSM Disorders (SCID)
intended for routine use by practicing clinicians, which
was performed by an ADE trained psychiatrist. The ADE
provided diagnoses of DSM IV bipolar I disorder, bipolar
II disorder, bipolar disorder not otherwise specified,
psychiatric and medical comorbidities, as well as mood
disorder history (Sachs et al. 2003). The ADE includes
standardized questions for subject report of the percent of
time in the prior 12 months spent experiencing mood ele-
vation, depression, or anhedonia symptoms. It also asks
for patient self-reported endorsement of a history of
premenstrual or postpartum mood exacerbation. As-
sessments of current mood state severity with Young
Mania Rating Scale (YMRS) (Young et al. 1978) and
Montgomery-Asberg Depression Rating Scale (MADRS)
(Montgomery and Asberg 1979) were performed by
two trained raters who periodically compared score
results for inter-rater reliability. Subjects completed
self-administered questionnaires detailing menstrual
and medical history and the Greene Climacteric Scale
(Greene 1976) to assess menopausal symptoms. A blood
sample was obtained in the early follicular phase of the
menstrual cycle to assess follicle-stimulating hormone
(FSH) and estradiol levels. In women who had not men-
struated for 60 days or longer, a random hormonal sample
was assessed.
Follow-up visits included standardized YMRS and
MADRS mood assessments. If a woman was men-
struating with predictability, visits would be sched-
uled up to 6 weeks apart in the early follicular phase
(days 2–6) of her menstrual cycle and hormone
blood draws performed. If a woman had gone 60 days
without menstruation at intake visit, then mood
assessments were scheduled once a month and hormone
blood draws were scheduled every other month re-
gardless of where a woman was in her menstrual
cycle. The study was approved by the University of
Massachusetts Medical School Institutional Review
Board.
Serum hormone measures
Estradiol and follicle-stimulating hormone were analyzed
by institutional standard laboratory procedures. Estradiol
levels were assessed by Access Estradiol, a competitive
binding immune-enzymatic assay. FSH was assayed by
Access hFSH which is a sequential two-step immune-
enzymatic assay.
Menopausal status
Menopausal staging was determined using the execu-
tive summary of Staging of Reproductive Aging in
Women (STRAW) designed as a comprehensive basis
for assessing reproductive aging in research settings
(Harlow et al. 2012). Subjects were categorized based on
STRAW+ 10 stages: (1) second half of the late reproduct-
ive (subtle changes in menstrual cycle characteristics and
vasomotor symptoms), (2) early perimenopasue (increased
variability in menstrual cycle length defined as a persistent
difference of 7 or more days in the length of consecutive
cycles), (3) late perimenopause (no menstrual cycle in
60 days but menstrual bleeding in the last 12 months),
and (4) early postmenopause (no menstrual cycle in the
last 1–5 years). Given the small sample size, the repro-
ductive groups were collapsed.
As hormonal levels and menstrual cyclicity remain
relatively predictable in the earlier stages of the MT
(Harlow et al. 2012), the late reproductive and early
MT women were collapsed into one group, called early
transition. Hormonal levels show greater variability and
unpredictability during the later menopausal transition
stages, including the early postmenopause (Burger et al.
1999; Burger et al. 2007; Sowers et al. 2008a; Sowers et al.
2008b; Harlow et al. 2012). In accordance, the late
perimenopausal and early postmenopausal women were
collapsed into one group, called the late and early-post
transition group.
Statistical analysis
The two groups analyzed included (a) the early transi-
tion group, consisting of women in late reproductive
(n = 4) or early perimenopause (n = 17) phase, and (b)
the late and early-post transition, women in their late
perimenopause (n = 20) or early postmenopause (n = 15)
phase.
Chi-square (χ2) tests were used to compare categor-
ical variables, and two sample t tests with equal vari-
ance were utilized to test differences in continuous
variables by the two groups; Pearson correlation coef-
ficients measured the linear association between two vari-
ables (Sedgwick 2012). For the main outcome measure,
we analyzed longitudinal changes across visits for MADRS
and YMRS sums using generalized estimating equation
(GEE) methods to control for the correlation within the
subjects at the five study time points. Models were run
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examining potential associations between MADRS and
YMRS and menopausal stage categories (early vs. late/post),
adjusted for study visit (where visit 1 was used as the
referent category). We used an autoregressive covariance
structure in all of our GEE models. p values are reported
from a z test that a single regression coefficient was equal
to 0. We also tested the significance of difference among
the time effects as a multiple degrees of freedom chi-
square test. SAS software version 9.3 (SAS Institute, Cary,
NC) was used for the GEE modeling while SAS version
9.2 was used for the remaining analyses.
Results
Of 255 women screened, 99 were eligible and 57 enrolled.
One woman was dropped due to active illicit substance
abuse influencing mood at the time of enrollment. Of the
56 women who entered the study, 21 % (n = 12) com-
pleted only the first visit, 32 % (n = 18) completed two
visits, and 66 % (n = 37) completed all third, fourth, and
final visits. The dropout rate in the early transition group
was 43 % and the late and early-post transition group
31 %. There were no significant differences in demo-
graphic characteristics, bipolar disorder characteristics, or
treatment approach between the early transition and the
late and early-post transition groups with the exception of
age-dependent variables (age and duration of illness) being
greater in the older aged late and early-post transition
group. Current alcohol use not meeting the criteria for de-
pendence or abuse was more common in the early transi-
tion group. There was no significant difference between
reproductive groups in other common comorbidities that
have been shown to affect mood course in BD including
rapid cycling status, age at onset (Schurhoff et al. 2000),
current comorbid anxiety (Simon et al. 2004), and sub-
stance use (Goldstein et al. 2006) disorders. The sample
characteristics are presented in Table 1.
Menopausal stage and mood
One woman who entered the study in late menopause
transitioned to early postmenopause during the study
observation. One woman who entered the study in early
menopause proceeded to late menopausal transition dur-
ing the study observation; she was analyzed in the early
transition group as the diagnosis of change of reproduct-
ive stage is made after the occurrence, as it would in
clinical practice.
A total of 44 women were included in this analysis, as
they had information from at least two visits in order to
adjust for the autocorrelation within women. Of these
women, 15 were in the early transition group and 29
were in the late and early-post transition (5 of which
were over the age of 55).
Results from the MADRS model showed that average
MADRS score was 4.43 points higher in the late and
early-post transition stage women compared to the early
transition women (±SE 2.14; p = 0.039), corresponding
to a roughly 10 % increase in score (score range 0–40)
in the late/post stage across all study visits. The effect of
time on the MADRS score was not significant (χ2 = 9.41;
df = 4; p = 0.052). The mean MADRS score for the early
transition women was 12.10 (±SE 1.63), 95 % CI 8.89,
15.30, and for the late and early-post transition women,
the mean was 16.52 (±SE 1.67) and 95 % CI 13.25, 19.80.
Results were similar for the YMRS model, where aver-
age score was 2.54 points higher in the late and early-
post transition women compared to the early transition
women (±SE 1.15; p = 0.027), also a roughly 10 % in-
crease (score range 0–26). The effect of time on the YMRS
score was not significant (χ2 = 8.68; df = 4; p = 0.07). The
mean YMRS score for early transition women was 6.06
(±SE 1.02), 95 % CI 4.07, 8.06, and for late and early-post
transition women, the mean was 8.60 (±SE 1.02), 95 % CI
6.60, 10.60.
In contrast, retrospective report of percent of past year
in depressed/anhedonic or elevated mood state was not
associated with menopausal stage (Table 2).
Table 1 Subject characteristics
Early MT
(n = 21)
Late MT/early
postmenopause
(n = 35)
p value Total
(n = 56)
Age, mean ± SD 45.0 ± 3.4 50.6 ± 4.7 <0.001 48.5 ± 5.0
Age at onset of bipolar
disorder, mean ± SD
14.9 ± 7.1 15.5 ± 8.6 0.82 15.3 ± 8.0
Bipolar diagnosis, N (%) 0.45
I 11 (53) 17 (48) 28 (50)
II 7 (33) 16 (45) 23 (41)
NOS 2 (14) 2 (6) 5 (9)
Duration of illness,
mean ± SD
30.0 ± 6.7 35.1 ± 8.6 0.02 33.2 ± 8.3
Rapid cycling, N (%) 13 (61.9) 24 (75) 0.31 37 (69)
Ethnicity, Caucasian,
non-Hispanic, N (%)
17 (80) 33 (97) 0.18 50 (91)
Marital status, married/
partnered, N (%)
10 (48) 19 (56) 0.55 29 (53)
Employment status,
full or part time, N (%)
8 (38) 14 (41) 0.82 22 (40)
BMI, mean ± SD 28.4 ± 5.7 31.3 ± 7.3 0.14 30.1 ± 6.8
Comorbid anxiety,
N (%)
19 (90) 33 (94) 0.60 52 (93)
Comorbid alcohol use,
N (%)
8 (38) 2 (6) <0.01 10 (18)
Comorbid substance
use, N (%)
3 (14) 8 (23) 0.43 11 (20)
Number of mood
stabilizers (Li, AED,
and antipsychotics),
mean ± SD
1.28 ± 0.8 1.25 ± 0.7 0.88 1.27 ± 0.7
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Neuroendocrine results
Mean FSH increased and mean estradiol decreased as
would be expected across the progression from early to
later menopausal transition to postmenopause (Table 3).
Estradiol levels varied by 264 pg/ml (19–283 pg/ml) for
FSH levels less than 40 IU/L; for FSH levels greater than
or equal to 40 IU/L, estradiol levels remained low <44 IU/L,
in accordance with the clinically accepted FSH cutoff
of 40 IU/L.
At initial visit, there was a positive correlation between
absolute estradiol level and YMRS (r(51) = 0.31, p = 0.02)
across reproductive groups. This significant association
was not born out when estradiol levels and YMRS scores
were assessed at follow-up visits. FSH levels were not
associated with YMRS score at intake or follow-up visits.
Neither FSH nor estradiol absolute levels were associ-
ated with MADRS scores at any visit. Likewise, the
amount of change in FSH or estradiol levels from the
previous visit to the assessed visit was not associated
with MADRS of YMRS score at any follow-up visit
(Table 4).
Menopausal symptoms and mood
Mean total Greene Climacteric Symptom rating was
23.4 (SD ± 10.7) in line with mean of 22.9 of normative
results of 40–55-year-old women visiting a menopausal
clinic. Greene score was significantly associated with
concurrent MADRS score, r(52) = 0.52, p < 0.001, but
not YMRS score at baseline visit. On sub-scale analysis,
MADRS score was associated with Greene Psychological
sub-scale, r(52) = 0.55, p < 0.001, but not with Greene
Vasomotor subscale (Table 5).
History of reproductive events and mood disruption
Women who had given birth (n = 36) and reported no post-
partum mood exacerbation tended to have lower, although
not statistically significant (t = −1.91, p = 0.07), mean YMRS
across visits (7.2 ± 7.0) than those who reported postpartum
mood exacerbations (YMRS 11.2 ± 5.5). Otherwise, re-
ported history of a postpartum and or perimenstrual mood
exacerbation was not associated with mean severity of
MADRS or YMRS in the MT and early postmenopausal
years (Table 6).
Discussion
The primary finding of this study is significantly higher
depression and mood elevation symptom scores in women
with bipolar disorder during the late menopausal transi-
tion and early postmenopause than those of women in the
late reproductive years and early menopausal transition.
A difference of greater than two points on the MADRS
(4.4 points in this report) has been called clinically
meaningful (Kennedy et al. 2006). A YMRS difference of
2.5 points reported in this study, even in an outpatient
population, while statistically significant, is less likely to be
clinically significant (Lukasiewicz et al. 2013).
The increased level of depressive symptoms in the late
and early-post transition group is consistent with previ-
ous chart reviews (Marsh et al. 2012) and retrospective
recall (Blehar et al. 1998; Freeman et al. 2002) of the MT
in women with bipolar disorder. It is also in agreement
with the greater rates, compared to premenopause, of
depression during the late MT (Schmidt et al. 2004;
Freeman 2010; Freeman et al. 2014) and often early
postmenopause (Bromberger et al. 2010) found in the
unipolar depression literature. The statistically signifi-
cant higher YMRS mood elevation rating in the late and
early-post transition group than early transition group is
in contrast to the decrease in DSM IV mood elevation
symptoms reported previously (Marsh et al. 2012) but
does not contradict the retrospective report of worsen-
ing mood elevation or irritability retrospectively reported
by many postmenopausal women with bipolar disorder
(Blehar et al. 1998; Freeman et al. 2002). The concomi-
tant worsening of both depression and mood elevation
symptoms in the later stages of the menopausal transi-
tion may be indicative of worsening of mixed features,
now a DSM V specifier for bipolar disorder (APA 2013).
Given these early results, future studies are needed, par-
ticularly with a larger sample size to confirm, or refute,
the menopausal transition as a time of risk of depression,
mood elevation or mixed symptoms in the course of bipo-
lar disorder. Larger studies would further elucidate the
role of clinically defined menopausal stage by evaluating
late reproductive, early transition, late transition, early
postmenopause, and late postmenopause. A longer dur-
ation of observation would ideally include observing mood
Table 2 Bipolar depression and mood elevation reported in the
previous year by menopausal stage
Menopausal stage
Early MT
(n = 21)
Late MT/early
postmenopause
(n = 35)
p value
% of previous year reported
in a depressed mood
36.3 ± 32.1 39.5 ± 26.2 0.69
% of previous year reported
in an elevated mood
10.3 ± 11.6 16.5 ± 17.5 0.16
Table 3 Reproductive hormone levels by menopausal stage
FSH (IU/L) Estradiol (pg/ml)
N Mean ± SD p value Mean ± SD p value
Early MT 20 11.6 ± 11.4 <0.0001 74.4 ± 63.8 =0.09
Late MT 19 53.1 ± 47.6 53.8 ± 69.3
Early
postmenopause
14 79.9 ± 33.2 27.9 ± 26.3
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across menopausal stages within individual subjects. Of
particular interest would be the role of the last menstrual
period as a marker in the late transition and early post-
menopause (Freeman et al. 2014) and as an easy reference
point in the clinical discussion with a patient.
Neuroendocrine
This is the first study to examine reproductive hormones
in the MT in bipolar disorder. Despite a positive correl-
ation between absolute estradiol level and YMRS at the
initial visit, there were no further associations between
absolute or change between visits in FSH or estradiol
levels with either depression or mood elevation scores.
While potentially a chance association of estradiol and
mood elevation symptoms, this is the first report on es-
tradiol levels and mood elevation. This result may indi-
cate a subgroup of women who are vulnerable to mood
elevation symptoms during times of high estradiol. No
standard testing exists for assessing the degree of vari-
ability in hormonal levels after cessation of predictable
menses, thus a potential future definition of variability,
may yet reveal associations with mood severity.
Neurocognitive evidence suggests that estradiol may
have antidepressant-like properties in the brain (Kendall
et al. 1982; McEwen et al. 1997), and clinical trial results
have reported an antidepressant effect of estradiol ad-
ministration during the MT in unipolar depression
(Soares et al. 2001; Rasgon et al. 2002). Nonetheless, re-
sults in unipolar depression during the MT overall do
not relay an association of depressive symptoms with
absolute FSH or estradiol levels (Schmidt et al. 2004;
Bromberger et al. 2010) with the exception of increased
FSH being positively associated with depressive symp-
toms in one study (Freeman et al. 2006). Reports on es-
tradiol and FSH variability and risk of depression during
the MT have been both positive (Freeman et al. 2004a;
Freeman et al. 2006; Freeman et al. 2014) and negative
(Schmidt et al. 2004; Bromberger et al. 2010; Freeman
et al. 2014) and have employed differing ways of asses-
sing variability.
More thorough hormonal assessments should include
testosterone which has been found associated with uni-
polar depression during the MT (Bromberger et al.
2010), inhibin B, an early indicator of ovarian aging,
and potentially sex hormone-binding globulin as well as
dehydroepiandrosterone which have both been assessed
in association with unipolar depression during the
menopausal transition (Bromberger et al. 2010).
Greene Climacteric Scale and vasomotor symptoms
This is the first evaluation of bipolar mood symptoms
and menopausal symptoms. The Greene Climacteric
Scale overall score was positively associated with concur-
rent depressive symptoms in women with bipolar dis-
order during the MT. This was driven by the Greene
psychological subscale association with MADRS depres-
sion scores. MADRS depression scores in women with
bipolar disorder were not associated with concurrent
vasomotor symptoms reported on the Greene Scale.
While the mechanism behind VMS is not well under-
stood, an association between vasomotor symptoms and
unipolar depressive symptoms has often (Cohen et al.
2006; Freeman et al. 2009) but not always been reported
(Freeman 2010).
The Greene Scale overall and subscale scores were not
associated with mood elevation symptoms. Thus, despite
the supposition that hormonal changes during the tran-
sition are behind VMS and the increased risk of unipolar
depression as well as the overlap in menopause and
mood symptoms (example sleep changes), the associ-
ation of menopausal and mood symptoms did not bear
out in bipolar disorder. As this is a cross-sectional
report, it may be useful to further examine the duration
of VMS or menopausal symptoms and risk of mood
symptoms and assess for the potential of a longitudinal
association.
Table 4 Bipolar depression and mood elevation score correlation with between-visit change in hormone levels
Visit N MADRS and change in FSH MADRS and change in estradiol YMRS and change in FSH YMRS and change in estradiol
1–2 24 r(22) = 0.22p = 0.29 r(22) = 0.22p = 0.30 r(22) = −0.01p = 0.97 r(22) = 0.03p = 0.90
2–3 16 r(14) = −0.09p = 0.72 r(14) = 0.16p = 0.56 r(14) = −0.14p = 0.6 r(14) = 0.29p = 0.28
3–4 19 r(17) = −0.20p = 0.41 r(17) = 0.02p = 0.92 r(17) = −0.29p = 0.22 r(17) = 0.34p = 0.16
4–5 18 r(16) = 0.15p = 0.54 r(16) = 0.01p = 0.97 r(16) = 0.20p = 0.43 r(16) = −0.40p = 0.10
Table 5 Greene Climacteric Symptom scale overall and subsection
correlation with bipolar depression and mood elevation scores
Greene MADRS
N = 54
YMRS
N = 54
Overall r(52) = 0.52 r(52) = 0.06
p < 0.0001 p = 0.66
Subsection
Somatic r(52) = 0.24 r(52) = 0.19
p = 0.09 p = 0.21
Vasomotor r(52) = 0.19 r(52) = −0.22
p = 0.16 p = 0.23
Psychological r(52) = 0.55 r(52) = 0.08
p < 0.001 p = 0.59
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History of reproductive-related mood exacerbations
Women who reported a mood exacerbation during the
postpartum period tended to experience more mood
elevation symptoms during the MT than women who did
not have a mood exacerbation in the postpartum. Depres-
sion scores in the MT did not significantly differ when a
woman reported history of postpartum and or perimenstr-
ual mood exacerbation. Likewise, mood elevation symp-
toms in the MT did not significantly differ if a woman
reported a history of perimenstrual mood changes or peri-
menstrual and postpartum mood exacerbations.
A case series reports postpartum mood episodes associ-
ated with an increased risk of perimenopausal mood epi-
sodes in bipolar disorder (Robertson Blackmore et al.
2008). Ours and other previous work in bipolar disorder,
in line with this study results, did not find reporting a
menstrual cycle or postpartum mood exacerbation associ-
ated with perimenopausal depression (Payne et al. 2007;
Marsh et al. 2012). In the unipolar depression literature,
the results are mixed. Women, in one study reporting pre-
menstrual symptoms, were at greater risk of menopausal
depressed mood (Freeman et al. 2004b); however, this was
not the case in a cross-sectional report in unipolar depres-
sion during the perimenopause (Steinberg et al. 2008).
The strength of this study is that it is the first to pro-
spectively evaluate mood during the MT in women with
bipolar disorder. The assessment of reproductive hormo-
nal levels and mood in women with bipolar disorder has
also not been reported prior. Likewise, VMS in women
with bipolar disorder had not been previously re-
ported in relation to mood. The limitations of this
study include a small sample size due to higher than
anticipated dropout and slow recruitment. The sample
was too small to further evaluate early MT, late MT,
and early postmenopause as separate groups. This
study is also unable to differentiate what part, if any,
the worse mood ratings in the older aged late and
early post transition group may be due to worsening
course of bipolar disorder with longer duration of the
mental illness. Life stressors were not assessed.
Conclusions
In summary, women with bipolar disorder were found to
have significantly more depression and mood elevation
symptoms during the late MT and early postmenopause
compared to late reproductive age and early MT women.
Overall, absolute levels and variability in FSH and estra-
diol were not associated with concurrent depression or
mood elevation mood ratings despite an initial positive as-
sociation of estradiol level and YMRS score at first visit.
Menopausal symptoms, but not specifically VMS, were
associated with concurrent depression but not mood ele-
vation severity. A history of postpartum mood exacerba-
tions may be associated with greater mood elevation
symptoms during the MT. Further studies of greater
duration are needed to discern whether the final men-
strual period is pivotal in mood pattern in the late MT to
early postmenopausal years. Knowing that, greater mood
Table 6 Difference in bipolar depression and mood elevation scores during the menopausal transition based on history of
reproductive phase mood exacerbation
Reproductive group Reproductive phase
mood exacerbation
(by woman), N (%)
Mean MADRS ± SD t test p value Mean YMRS ± SD t test p value
Perimenstrual
Nwomen = 55
History of perimenstrual
mood exacerbation
47 (85) 15.4 ± 8.5 t = 0.20 p = 0.85 9.0 ± 6.1 t = −0.59 p = 0.56
No history of perimenstrual
mood exacerbation
8 (15) 16.1 ± 14.8 7.6 ± 7.2
Postpartum
Nwomen = 46
History of postpartum
mood exacerbation
23 (64) 14.4 ± 7.9 t = 0.33 p = 0.74 11.2 ± 5.5 t = −1.91 p = 0.07
No history of postpartum
mood exacerbation
13 (36) 15.5 ± 10.8 7.2 ± 7.0
Perimenstrual and postpartum
(Nwomen = 46)
Both: history of postpartum
and perimenstrual mood
exacerbation
20 (91) 14.3 ± 8.0 t = 0.97 p = 0.34 10.9 ± 5.8 t = −0.75 p = 0.46
Neither: no history of postpartum
or perimenstrual mood exacerbation
2 (9) 21.0 ± 22.6 7.5 ± 10.6
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severity symptoms occurred during times of greater
hormonal variability during the menopausal transition
(the late MT and early postmenopause) may offer an
opportunity to examine novel hormonal approaches to
mood stability in women with bipolar disorder.
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